Literature DB >> 19199984

Designing multiple ligands - medicinal chemistry strategies and challenges.

Richard Morphy1, Zoran Rankovic.   

Abstract

It has been widely recognised over the recent years that parallel modulation of multiple biological targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease. In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a number of illustrative example are given. Designing multiple ligands is frequently a challenging endeavour for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets whilst obtaining physicochemical and pharmacokinetic properties that are consistent with the administration of an oral drug. Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199984     DOI: 10.2174/138161209787315594

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  46 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Virtual screening for potential inhibitors of bacterial MurC and MurD ligases.

Authors:  Tihomir Tomašić; Andreja Kovač; Gerhard Klebe; Didier Blanot; Stanislav Gobec; Danijel Kikelj; Lucija Peterlin Mašič
Journal:  J Mol Model       Date:  2011-06-12       Impact factor: 1.810

3.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

4.  Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

Authors:  Henry I Mosberg; Larisa Yeomans; Aubrie A Harland; Aaron M Bender; Katarzyna Sobczyk-Kojiro; Jessica P Anand; Mary J Clark; Emily M Jutkiewicz; John R Traynor
Journal:  J Med Chem       Date:  2013-02-27       Impact factor: 7.446

Review 5.  Lost but making progress--Where will new analgesic drugs come from?

Authors:  David Borsook; Richard Hargreaves; Chas Bountra; Frank Porreca
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

6.  Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering.

Authors:  Daniel Moser; Joanna M Wisniewska; Steffen Hahn; Janosch Achenbach; Estel la Buscató; Franca-Maria Klingler; Bettina Hofmann; Dieter Steinhilber; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2012-01-17       Impact factor: 4.345

7.  Insights into the Impact of a Membrane-Anchoring Moiety on the Biological Activities of Bivalent Compounds As Potential Neuroprotectants for Alzheimer's Disease.

Authors:  Liu He; Yuqi Jiang; Kai Liu; Victoria Gomez-Murcia; Xiaopin Ma; Alejandro Torrecillas; Qun Chen; Xiongwei Zhu; Edward Lesnefsky; Juan C Gomez-Fernandez; Bin Xu; Shijun Zhang
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

Review 8.  Rationally designed multitarget agents against inflammation and pain.

Authors:  S H Hwang; A T Wecksler; K Wagner; B D Hammock
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

9.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

10.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.